Corticotropin-releasing Hormone and Its Biological Diversity toward Angiogenesis.
Corticotropin-releasing Hormone and Its Biological Diversity toward Angiogenesis.
复制标题
DOI：
10.5217/ir.2014.12.2.96
复制
发表时间：
2014-04
影响因子：
4.9
通讯作者：
Im E
中科院分区：
文献类型：
--
作者：
Im E
血管生成是从现有的血管形成新的血管，是许多人类疾病的根本原因，包括癌症和炎症。大量证据表明，血管生成抑制剂在治疗血管疾病方面具有潜在的治疗潜力。然而，不良反应和低疗效阻碍了它们在临床上的应用。促肾上腺皮质激素释放激素(CRH)家族成员包括促肾上腺皮质激素释放激素(CRH)、尿皮质激素I-III和CRH受体(CRHR)1和2，广泛表达于大脑和周围组织，包括肠道和心血管系统。CRH家族通过下丘脑-垂体-肾上腺轴调节应激反应。针对CRH家族成员的治疗药物为各种胃肠道疾病的治疗提供了一种新的方法，包括肠易激综合征(IBS)、炎症性肠病(IBD)和结直肠癌。自从发现CRHR 2在小鼠出生后发育过程中具有抗血管生成活性以来，CRH系统在调节血管形成和心血管功能中的作用成为研究的重点。这篇综述将概述CRH家族成员的基本生物学功能以及对新的抗血管生成药物开发的意义。
Angiogenesis is the formation of new blood vessels from existing ones and an underlying cause of numerous human diseases, including cancer and inflammation. A large body of evidence indicates that angiogenic inhibitors have therapeutic potential in the treatment of vascular diseases. However, detrimental side effects and low efficacy hinder their use in clinical practice. Members of the corticotropin-releasing hormone (CRH) family, which comprises CRH, urocortin I-III, and CRH receptors (CRHR) 1 and 2, are broadly expressed in the brain and peripheral tissues, including the intestine and cardiovascular system. The CRH family regulates stress-related responses through the hypothalamic-pituitary-adrenal axis. Therapeutic agents that target CRH family members offer a new approach to the treatment of various gastrointestinal disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and colorectal cancer. Since the discovery that CRHR 2 has anti-angiogenic activity during postnatal development in mice, studies have focused on the role of the CRH system in the modulation of blood vessel formation and cardiovascular function. This review will outline the basic biological functions of the CRH family members and the implications for the development of novel anti-angiogenic therapies.